Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan liposome + camrelizumab + fluorouracil for metastatic esophageal squamous cell carcinoma after failure of first-line therapy
ChiCTR2600126181Phase 2Not yet recruiting
- Sponsor
- The Affiliated Hospital of Yangzhou University
- Start
- Jun 2026
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of irinotecan liposome, camrelizumab and fluorouracil in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by The Affiliated Hospital of Yangzhou University. Primary endpoint: Objective response rate. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
irinotecan liposomecamrelizumabfluorouracil
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2600126181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126181.